News
We send the latest information from SMC Laboratories.
Lipocine announces positive topline Phase 2 results from LPCN1144 ongoing Lift study in biopsy-confirmed NASH subjects
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT …
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-10…
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For deta…
CytoDyn announces first patient enrolled in Phase 2 study for NASH
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 …
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifib…
Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~
Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Exp…
Virginia Comonwealth University's publication in Journal of lipid research
SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAM…
University of Yamanashi's publication in Clinical and Experimental Gastroenterology
SMC announces that University of Yamanashi (Japan) has published the results of a study using STAMTM mouse mod…
Aldafermin improves fibrosis in patiants with NASH
NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its p…
89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH
89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89…